Not available
Quote | Cellectis S.A. (NASDAQ:CLLS)
Last: | $2.47 |
---|---|
Change Percent: | -2.85% |
Open: | $2.53 |
Close: | $2.47 |
High: | $2.63 |
Low: | $2.3 |
Volume: | 14,972 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
News | Cellectis S.A. (NASDAQ:CLLS)
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new ...
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preliminary data exp...
Message Board Posts | Cellectis S.A. (NASDAQ:CLLS)
Subject | By | Source | When |
---|---|---|---|
https://ih.advfn.com/stock-market/NASDAQ/cellectis-$CLLS/stock-news/83912184/cell | Frankestin | investorshub | 01/10/2023 5:27:59 PM |
Cellectis Announces Positive Preliminary Clinical Data for UCART22 | Frankestin | investorshub | 12/14/2022 8:39:18 AM |
will there be something interesting? | Frankestin | investorshub | 11/01/2022 10:53:45 AM |
also interesting here! | Frankestin | investorshub | 06/01/2022 5:10:36 PM |
News: $CLLS Cellectis and Lonza Enter cGMP Manufacturing | whytestocks | investorshub | 10/01/2019 8:40:21 PM |
News, Short Squeeze, Breakout and More Instantly...
Cellectis S.A. Company Name:
CLLS Stock Symbol:
NASDAQ Market:
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneerin...
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new ...
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneerin...